Skip to main content

Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.

Publication ,  Journal Article
Stout, JE; Engemann, JJ; Cheng, AC; Fortenberry, ER; Hamilton, CD
Published in: Am J Respir Crit Care Med
March 15, 2003

An alternative regimen for the treatment of latent tuberculosis infection is 2 months of rifampin and pyrazinamide, but some patients have died of hepatitis associated with this therapy. One hundred fourteen patients received rifampin/pyrazinamide in Wake County, North Carolina, between December 1999 and May 2002; 60.5% of these patients were homeless, and at least 17% drank alcohol to excess. Seventy-seven patients (67.5%) completed a full 2-month course. Nine patients had a history of viral hepatitis or chronic liver disease. Four of 114 (3.5%; 95% confidence interval, 1.0-8.7%) patients developed hepatitis on therapy, and another two had symptoms consistent with hepatitis but did not report for laboratory testing (total confirmed plus suspected hepatitis rate 5.3%; 95% confidence interval, 2.0-11.1%). No patient who developed hepatitis had a history of viral hepatitis or liver disease, and none had been previously treated with isoniazid. No patients died or were hospitalized due to drug side effects. Rifampin/pyrazinamide was associated with a significantly higher rate of hepatitis than previously described with isoniazid therapy for latent tuberculosis but resulted in a high completion rate. The rifampin/pyrazinamide regimen for latent tuberculosis infection may be useful for high-risk, traditionally nonadherent patient groups, but careful monitoring for toxicity is required.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Respir Crit Care Med

DOI

ISSN

1073-449X

Publication Date

March 15, 2003

Volume

167

Issue

6

Start / End Page

824 / 827

Location

United States

Related Subject Headings

  • Tuberculosis
  • Treatment Outcome
  • Safety
  • Rifampin
  • Respiratory System
  • Pyrazinamide
  • North Carolina
  • Middle Aged
  • Male
  • Liver Diseases
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stout, J. E., Engemann, J. J., Cheng, A. C., Fortenberry, E. R., & Hamilton, C. D. (2003). Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med, 167(6), 824–827. https://doi.org/10.1164/rccm.200209-998OC
Stout, Jason E., John J. Engemann, Allen C. Cheng, Ellen R. Fortenberry, and Carol D. Hamilton. “Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.Am J Respir Crit Care Med 167, no. 6 (March 15, 2003): 824–27. https://doi.org/10.1164/rccm.200209-998OC.
Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med. 2003 Mar 15;167(6):824–7.
Stout, Jason E., et al. “Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.Am J Respir Crit Care Med, vol. 167, no. 6, Mar. 2003, pp. 824–27. Pubmed, doi:10.1164/rccm.200209-998OC.
Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med. 2003 Mar 15;167(6):824–827.

Published In

Am J Respir Crit Care Med

DOI

ISSN

1073-449X

Publication Date

March 15, 2003

Volume

167

Issue

6

Start / End Page

824 / 827

Location

United States

Related Subject Headings

  • Tuberculosis
  • Treatment Outcome
  • Safety
  • Rifampin
  • Respiratory System
  • Pyrazinamide
  • North Carolina
  • Middle Aged
  • Male
  • Liver Diseases